Phenylketonuria

Kimberly A Chapman MD PhD (

Dr. Chapman of Children’s National Health System has no relevant financial relationships to disclose.

)
Debra S Regier MD PhD (

Dr. Regier of Rare Disease Institute, Children’s National Medical Center, has no relevant financial disclosures to disclose.

)
Barry Wolf MD PhD, editor. (Dr. Wolf of Lurie Children's Hospital of Chicago has no relevant financial relationships to disclose.)
Originally released March 30, 1995; last updated March 5, 2018; expires March 5, 2021

This article includes discussion of phenylketonuria, atypical hyperphenylalaninemia, hyperphenylalaninemia, malignant hyperphenylalaninemia, and PKU. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.

Overview

In this article, the authors review the history of the discovery of phenylketonuria, one of the oldest known inborn errors of metabolism, and review the development of dietary treatment and neonatal screening for this disorder. The pathophysiologic mechanisms that are thought to cause central nervous system damage are discussed. New FDA-approved treatments and treatments in trial are revolutionizing the treatment of phenylketonuria in the 21st century.

Key points

 

• Phenylketonuria is caused by deficient activity of phenylalanine hydroxylase, an enzyme in the intermediary metabolism of the amino acid, phenylalanine, and is one of the most common inborn errors of metabolism.

 

• Phenylketonuria is inherited as an autosomal recessive disorder.

 

• Neonatal screening for phenylketonuria allows for the early detection and treatment of infants with the disorder.

 

• Dietary therapy of phenylketonuria is based on restriction of dietary phenylalanine intake and largely prevents the major manifestations of the disorder, including profound developmental disability and seizures, but there are difficulties with lifelong adherence to the diet that may lead to cognitive impairment, particularly problems with executive functioning.

 

• Novel therapeutic approaches for phenylketonuria include sapropterin dihydrochloride treatment of a subset of patients who are responsive to the drug, large neutral amino acid supplementation to block phenylalanine uptake into brain, and enzyme substitution therapy with polyethylene glycol-conjugated phenylalanine ammonia lyase.

Historical note and terminology

In 1934, Følling reported a compound in the urine of 2 developmentally disabled individuals that reacted with ferric chloride to produce a deep green color. He subsequently identified this compound as phenylpyruvic acid in the urine of 10 developmentally delayed individuals (Folling 1934). Penrose and Quastel named the disease "phenylketonuria” and first attempted dietary therapy (Penrose and Quastel 1937). The metabolic defect in phenylketonuria was determined to be impaired hydroxylation of phenylalanine to tyrosine (Jervis 1947), and the liver enzyme phenylalanine hydroxylase was ultimately shown to be deficient in individuals with phenylketonuria (Jervis 1953). With the development of a simple bacterial inhibition assay, known as the Guthrie test (Guthrie and Susi 1963), and along with the successful treatment by dietary restriction of phenylalanine using synthetic diets (Bickel et al 1953), neonatal screening and early treatment were introduced. Most neonatal screening programs have now discontinued the use of the Guthrie test to detect elevated phenylalanine concentrations in favor of the faster, more sensitive tandem mass spectrometry method that also detects several other amino acidopathies. The human gene encoding phenylalanine hydroxylase was cloned in 1983 (Woo et al 1983).

With the successful treatment of phenylketonuria, a group of individuals were identified who, despite dietary restriction of phenylalanine, had progressive neurologic disease and were designated as having "malignant phenylketonuria." These children patients were found to have a deficiency of 1 of the enzymes of tetrahydrobiopterin metabolism. Tetrahydrobiopterin is a necessary cofactor for phenylalanine hydroxylase, tyrosine-3-hydroxylase, and tryptophan-5-hydroxylase (the latter 2 are rate-limiting enzymes in the synthesis of catecholamines and serotonin, respectively), and all forms of nitric oxide synthase. In addition to being hyperphenylalaninemic, children with defects in the metabolism of tetrahydrobiopterin exhibit deficiency of biogenic amine neurotransmitters in the central nervous system. Treatment by dietary phenylalanine restriction alone is not successful, but must be combined with tetrahydrobiopterin replacement and administration of L-DOPA and 5-hydroxytryptophan to address the neurotransmitter deficiencies.

Nomenclature for this group of inborn errors of metabolism can be confusing because of the great phenotypic variability (Regier and Greene 2017). The 2014 American College of Medical Genetics and Genomics guidelines on the diagnosis and management of phenylalanine hydroxylase deficiency recommend that the term “phenylalanine hydroxylase (PAH) deficiency” be used to describe all affected individuals who previously have been described as having phenylketonuria. In this review, we will use the historical term “phenylketonuria.” This supports the concept that there is a spectrum of phenylalanine hydroxylase deficiency. This guideline recommends a unifying nomenclature and, therefore, refers to the spectrum of phenylalanine hydroxylase deficiency, not specifically relying on the blood phenylalanine concentration; although the guidelines recognize that the most severe form is still likely to be referred to as “classical phenylketonuria” in many settings. Historically, those with the most severe phenylalanine hydroxylase deficiency had untreated blood phenylalanine concentrations typically greater than 1200 μmol/l (mean normal concentration: 60 µmol/l) and were called “classical phenylketonuria”. On the milder side of the spectrum, patients with untreated blood phenylalanine concentrations greater than normal concentrations, but less than 1200 μmol/l, were previously described as having hyperphenylalaninemia.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.